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ABSTRACT 
Antimicrobial resistance threatens the effective prevention and treatment of an increasing range of 
Infections. The ongoing discovery of newer antimicrobial resistance has been a driving energy in 
the design, synthesis and development of newer antimicrobial agents. As a contribution to these 
efforts, we synthesized novel Bromopyrrole-Cinnamaldehyde Hybrids compounds. A series of 
fifteen Bromopyrrole-Cinnamaldehyde Hybrids molecules were synthesized by molecular 
hybridization approach. In vitro anti-mycobacterial activity of synthesized compounds was 
evaluated against Mycobacterium tuberculosis H37Rv strain. Among the series, 4(b-e) exhibited 
activity (MIC >20 μM; IC50 = >20 μM) furthermore the sythesised hybrids displayed promising 
activity against tested fungal strains, in particular for clinical isolate of C. neoformans with MIC 
values ranging from 12.5 – 25 µg/mL. All synthesized compounds were confirmed by melting 
point, FT-IR, 1H-NMR and 13C-NMR spectroscopy. The yield of these compounds obtained 
ranged from 40% to 80%.  
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1.1. BACKGROUND AND RATIONAL OF THIS STUDY 
This work is an effort towards understanding Bromopyrrole-Cinnamaldehyde hybrids in drug discovery 
and its’s antitubercular and antimicrobial activity. TB is a communicable disease caused by the bacillus 
Mycobacterium tuberculosis. It’s known to primarily affect the lungs (pulmonary TB). There are five 
closely related mycobacteria responsible for tuberculosis: Mycobacterium. Tuberculosis, Mycobacterium 
bovis, Mycobacterium africanum, Mycobacterium microt and Mycobacterium. Canet. M. tuberculosis, by 
far the commonest, is transmitted between humans through the airborne route. 1–5 
 
A study by Clare V. Smith et al allude to the fact that among the main obstacles to the global control of the 
disease are emerging multi-drug resistant strains and the recalcitrance of persistent infections to treatment 
with conventional anti-TB drugs and studies reviewing the recent developments to understanding some of 
the pathways involved in a persistent infection and pathogenesis of Mycobacterium tuberculosis, reveals 
the need for development of structure-based drug design as the current TB drug are said to  have major 
adverse reactions that can cause significant morbidity and compromise treatment regimen for TB.6–9 
 
Bromopyrroles and cinnamaldehyde respectively are natural occurring products reported as having 
important synthetic and biological activities. Bromopyrrole derivatives has potent antibacterial and 
antifungal activity, a study by. Akbar Idhayadhulla et al concludes that synthesized pyrrole compounds 
screened against E. coli and S. aureus for antibacterial activity, as well as against A. Niger and C. 
albicans for antifungal activity had higher or equal potency to the reference compounds 
Ciprofloxacin and Clotrimazole. Cinnamaldehyde on the other hand showed significant inhibitory activity 
against the microbes, using streptomycin as a standard and this study concludes that the synthesized 
compound shows excellent antibacterial activity especial against Staphylococcus aureus. Activity against 
only Escherichia coli and Pseudomonas aeraginosa the synthesized compounds exhibit significant 
antioxidant activity using ascorbic Acid as a standard.9–13   
 
Inspired by the evidence from the literature review above this thesis is directed at investigating the anti-
tubercular and antimicrobial activity potential when combining Bromopyrroles and cinnamaldehyde to 
form novel Bromopyrroles – cinnamaldehyde hybrids. 
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1.2. AIMS OF THIS STUDY 
1.2.1 To synthesize Bromopyrrole-Cinnamaldehyde hybrids 
1.2.2 To evaluate the synthesized compounds against anti- microbial and anti-tuberculosis 
strains 
 
1.3. OBJECTIVES OF THIS STUDY 
1.3.1 To synthesize Bromopyrrole-Cinnamaldehyde hybrids by molecular hybridization process  
1.3.2 To carry out anti-tubercular testing against H37Rv  
1.3.3 To carry out antimicrobial testing against a panel of gram-negative, gram-positive bacteria and 
fungal strains employing a minimum inhibitory concentration (MIC) technique 
 
1.4. OVERVIEW OF THIS THESIS 
This has 5 chapters, outlined as follows: 
 
Chapter 1: This chapter addresses the background, aim and objectives, structure of the thesis. 
 
Chapter 2: Provides a historic background of antimicrobials followed by their mechanism of action and 
resistant, a brief history on tuberculosis and its resistant and the current drug treatment and justification of 
research  
 
Chapter 3: This chapter provides experimental data, description of different spectroscopic techniques 
employed to confirm the formation of the desired novel target compounds and their schematic 
representation. The chapter also displays a concise synthetic strategy and mechanisms of the entire reaction 
leading to the formation of the novel compounds. Procedures or assay methods employed to evaluate the 
biological activity have also been explained in this chapter. 
 
Chapter 4: This chapter highlights the results obtained during the course of the research and their 
discussion. Physio-chemical properties of the synthesized derivatives such as appearance, molecular weight 
and percentage yield observed have been reported. The chapter also focuses on spectroscopic 
characterization data to verify the formation of the compounds and lists some examples of spectra obtained 
with respect to synthesized compounds. 
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Chapter 5: This chapter focuses on general concluding remarks and future scope of the research work 
which includes building more library of novel compounds for Bromopyrrole-Cinnamaldehyde hybrids. 
 
Appendix: This section reflects all the NMR and IR spectra obtained for all synthesized derivatives during 
the course of the research work 
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2.1.  Review on Antimicrobial Agents: 
An antimicrobial is an agent that eradicates or impedes the growth of microbes with minimal or 
no harm to the host. Antimicrobials are classified based on their activity, effect on microorganisms 
and mode of action. For instance, agents that act against bacterial are called antibacterial, viruses 
(antiviral), fungi (antifungal) and protozoa (anti protozoal). [1][2] 
Historically, antimicrobials began with the observation made by Pasteur and Koch, who 
discovered that a particular type of bacteria prevented the growth of the other bacterial. At the time 
of discovery, they were unable to establish a tangible evidence of the plausible mechanism of 
action.   In the 18th century, a blue-green pigment which was a by-product from culture of Bacillus 
pyocyaneus (Pseudomonas aeruginosa) became the first recorded microbial agent to demonstrate 
antimicrobial activity, but its instability and inherent toxicity in patients resulted in a decline in its 
usage.[3] Before the 20th century it became evident that the microorganisms were liable for the 
cause of various microbial infections, consequently this led to an exciting race of discovery of 
antimicrobial agents. [3] The first chemical compound to have shown proficiency in treatment 
microbial disease in humans notably syphilis was Salvarsan (1) discovered by Paul Ehrlich in 
1910. In September 1928, a Scottish scientist called Alexander Fleming discovered that mold (a 
fungus from the penenicillium genus) impeded the growth of staphylococcus aureus.  The 
chemical entry was called penicillin (2). It was however only in the 1940’s when Florey and Chain 
made this penicillin available as a therapeutic agent. [4] 
In 1935, Domagk’s and co-workers developed the first sulfonamide compound as an antimicrobial 
agent, a synthetic red dye prontosil (3) that contains a sulfonamide group. Streptomycin (4) was 
then introduced in 1944; an aminoglycoside antibiotic obtained from the soil bacterium 
Streptomyces griseus, for the treatment of tuberculosis mutant strains of Mycobacterium 
tuberculosis. This was followed by the discovery of Chloramphenicol (5) in 1946 from a soil. [5] 
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Antibiotic Chemical Classification: 
Figure 1 Depicts an overview for antibiotic classification, their bactericidal and bacteriostatic 
action 
 
Figure 1: A Brief Overview of Classes of Antibiotics [78] 
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Figure 2: Structures of marketed drugs with antimicrobial activity. 
Antimicrobials have since evolved over a period of time and became the key constituents in the 
treatment of infectious disease caused by micro-organisms thus facilitating a better health for 
millions around the world. [6][7] Despite the critical role that these agents play in improving the 
health of patients, Antimicrobial Resistance (AMR) remains a threat in the effective prevention 
and treatment of the epidemic. The rate of emergence of resistance is higher than that of the 
antimicrobial agents discovery [7][8]. The threat, therefore poses an urgent call for development 
of new antimicrobial agents.  
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2.2. Mechanism of Action 
Research states that antimicrobial agents act against microbes by targeting specific receptors, thus 
having an inhibitory effect on the specific processes that are vital for the microbial advance or 
division. [9] The goal is to have highly selective toxicity towards these microbes with minimal or 
no toxicity in humans. The mode by which they execute this action includes: Inhibition of cell wall 
synthesis, alteration of cell membrane function, inhibition of protein synthesis and that of nucleic 
acid synthesis. [9] [10] 
2.3. Mode of action classification: 
2.3.1. Inhibition of cell wall synthesis 
The most crucial structure for the existence and endurance of the microbe is the cell wall. It has 
penicillin-binding proteins (PBPs) a group of enzymes anchored in the cell membrane responsible 
for the crosslinking of the bacterial cell wall. The group of antibiotics i.e.: penicllins, 
cephalosporins, carbapenems, monobactams, bacitracin and vancomycin has the beta-lactam ring 
portion that binds to these different PBPs, preventing them from performing their role in cell wall 
synthesis thus selectively killing the bacteria. Meanwhile, the binding of glycopeptides to 
precursors that are responsible for the bacterial cell wall synthesis, leads to the interference with 
the PBP enzymes, preventing transpeptidases to incorporate the precursors into the growing cell 
wall, this processes stops the cell wall synthesis and cell death often follows.[3][11] 
2.3.2. Alteration of cell membrane function  
Cell membranes are important enclosure that separate and control the intra- and extracellular 
constituents flow. The drugs that inhibits cell membrane function acts by interfering with the 
functional integrity of the cytoplasmic membrane causing macromolecules and ion escape from 
the cell which in turn leads to cell death or damage. Both eukaryotic and prokaryotic cells has this 
enclosure.  The class of antibiotics that alter the cell wall membrane can often be poorly selective 
and often toxic for systemic use, Examples: Amphotericin B and Colistin (polymixin) (6) 
[3].[10][12] 
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Figure 3: Structures of Colistin (Polymixin) [3] 
2.3.3. Inhibition of protein synthesis 
The vital process by that the bacterial cells multiply and thus increase their survival is called 
protein synthesis. Various antibacterial agents inhibits bacterial protein synthesis by binding to 
either the 30S or 50S subunits of the intracellular ribosomes. Examples of drugs that target the 
30’s subunit include: aminoglycosides and tetracyclines while the 50’s subunit drug targets are 
macrolides, chloramphenicol (7) and Tetracyclines (8). This binding subsequently leads to the 
death of the organism or inhibition of its growth.[3][11][13] 
      
 
Figure 4: Structures of Chloramphenicol and Tetracycline[3] 
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2.3.4. Inhibition of nucleic acid synthesis 
The mechanism of action includes the inhibition of deoxyribose nucleic acid (DNA) and ribose 
nucleic acid (RNA) synthesis. These nucleic acids are key in the replication of all living forms, 
including bacteria. There are antibacterial drugs that work by binding to mechanisms involved in 
the process of DNA or RNA synthesis[11]. They interfere with folic acid synthesis thus prevention 
the addition of paraaminobenzoic acid (PABA) into the folic acid molecule through competing for 
the enzyme dihydropteroate synthetase e.g. Sulfonamides, others interferes with the folic acid 
pathway by binding to the enzyme dihydrofolate reductase e.g. trimethoprim. Drugs that inhibit 
the DNA synthesis include fluoroquinolones, ciprofloxacin (9), with DNA gyrase being the 
primary target for fluoroquinolones. Rifampin (10) is rifamycin’s that blocks bacterial 
transcription by inhibiting the RNA polymerase, thus preventing bacterial replication. [3][11][14]  
 
Figure 5: Structures of Ciprofloxacin and Rifampicin 
2.4. Antimicrobial resistance (AMR)  
The therapeutic agent’s curative success is recognized by the potential development of tolerance 
or resistance to that agent from the time it is first clinically used, and this concept also applies for 
antibacterial gents. The emergence of resistance in most pathogens has rendered many clinically 
used antimicrobials ineffective, causing a major global health concern in humans. AMR is defined 
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as the ability of the pathogen to stay alive in the presence of an antimicrobial agent that would 
normally inhibit or kill it. In some cases bacterial pathogens progresses into multidrug-resistant 
(MDR) forms following the multiple antibiotic use, e.g. exposure to first, second and even third 
line generation of antibiotics.[7][2][15][16] 
2.5. Mechanistic basis of antimicrobial resistance  
These pathogens may manifest resistance to antimicrobial through three major strategies. To 
provide a comprehensive classification of the antibiotic resistance mechanisms, we will categorize 
them according to the biochemical route involved during resistance, as follows: (i) prevention of 
the compound reaching the antibiotic target (by decreasing penetration or actively extruding the 
antimicrobial compound), (ii) modifications of the antimicrobial molecule, and (iii) changes to 
and/or bypassing of target sites. [3][9][11] 
2.6. Decreased Antibiotic Penetration and Efflux  
2.6.1.  Decreased permeability 
Decreased permeability due to microbes modifying the cell membrane porin channel frequency, 
size, and selectivity thus preventing entry of antimicrobials to reaching their intended target sites. 
Some microbes may acquire gene-encoding enzymes, such as β-lactamases, that destroy the 
antimicrobial agent before it can have an effect.[17] 
2.6.2. Efflux pumps  
Efflux pumps can either have the capacity to pump a wide range of unrelated agents or be 
antimicrobials specific. Active flow out of drugs from the cell is one of the common mechanisms 
of antimicrobials resistance in bacteria. The process of drug resistance occurs when the percentage 
of drug flowing out across the membrane exceeds that of drug flowing as bacterial genomes 
encrypt numerous membrane-bound multidrug out flow systems (Fig 5) .[17][18] 
2.7. Modifications of the Antibiotic Molecule  
This occurs when the bacteria defend themselves by deactivating the active component of the 
antimicrobial agent. Research confirms that the same tactic has also been observed in 
Enterobacteriaceae against chloramphenicol (acetylation), Gram negative and Gram-positive 
bacteria against aminoglycosides (phosphorylation, adenylation, and acetylation). [19] 
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2.8. Target site modification 
To circumvent recognition by antimicrobials the bacteria reprogram or mask its critical target sites. 
This action prevents binding of any active antimicrobial agent to bacteria, this is predominantly 
noted in Staphylococci against methicillin and other beta-lactams (i.e. changes or acquisition of 
different PBPs that do not sufficiently bind to beta lactams to inhibit cell wall synthesis). It has 
also been observed in Enterococci against vancomycin (i.e. alteration in cell wall precursor 
components to decrease binding of vancomycin) Mycobacterium spp. against streptomycin (i.e. 
modification of ribosomal proteins or of 16s rRNA). Mutations in RNA polymerase confer 
resistance to the rifamycins while mutations in DNA gyrase result in resistance to quinolones. 
Antimicrobial resistance threatens, effective prevention and treatment of increasing range of 
infection and thus warrants scientific intervention to bring about action plans to curve this 
threat.[17]. Figure 6 highlight the therapeutic predominant antimicrobial targets and examples of 
the drugs for each target.  
 
Figure 6: Gerard D Wright. Antibiotic targets and mechanisms of resistance. BMC 
Biology 2010 8:123 [17] 
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2.9. Tuberculosis 
TB is a communicable disease caused by the bacillus Mycobacterium tuberculosis. It’s known to 
primarily affect the lungs (pulmonary TB), however it has been noted over the years that other site 
such as (extrapulmonary TB) can be affected too. Researchers still note it to remain a major global 
health problem, responsible for ill health among millions of people each year and it is ranked as 
the second leading cause of death from an infectious disease worldwide, after the human 
immunodeficiency virus (HIV). 
TB, Mycobacterium tuberculosis, is transmitted by droplets when an infected person coughs or 
sneezes. The unique clinical characteristics of this dangerous pathogen are a result of its high lipid 
content. Other M. tuberculosis complex (MTBC) include M. bovis, M. africanum, M. canetti, and 
M. microti. M. africanum, they are however not prevalent in other parts of the world, but they 
remain a significant cause of tuberculosis in many parts of Africa, especially in Southern Africa. 
The World Health Organization (WHO) 2014 global tuberculosis report estimates states that in 
2013 there were 9.0 million new TB cases and 1.5 million TB deaths (i.e. 1.1 million among HIV-
negative people and 0.4 million among HIV-positive people), This indicates an increase from 8·6 
million estimated in 2012. 
The current standard therapy for drug-sensitive tuberculosis despite being effective, they have 
longer drug regimen.  However, highly effective treatment with shorter regimens are required to 
reduce the burden of infectious cases.  This is even more crucial as the number of new cases of 
multidrug-resistant (MDR) tuberculosis caused by Mycobacterium tuberculosis resistant strains to 
at least rifampicin and isoniazid, and the extensively drug-resistant (XDR) tuberculosis to 
rifampicin, isoniazid, plus any fluoroquinolone and at least one of the three injectable second-line 
tuberculosis drugs, amikacin, kanamycin and capreomycin) continue to increase. 
MDR tuberculosis regimens treatment success rate is still low for both individualized and standard 
regimens, resulting in high death rates. These bleak treatment outcomes of MDR and XDR 
tuberculosis highlight the urgent need for the development of new antituberculosis drugs, treatment 
regimens, and other adjunct treatment approaches to improve treatment outcomes[20][21] 
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Figure 7: Estimated TB incidence rates in 2016[22] 
2.10. Anti- Tuberculosis Drugs 
Anti- Tuberculosis Drugs varying properties can be classified as: bactericidal, bacteriostatic 
(sterilizing) and those with the capability to prevent resistance. Six month is a recommended 
treatment period, however in some cases such as military meningitis and bone TB treatment may 
be extended to nine months, however treatment for multi drug resistant TB (MDR-TB) and 
extensively drug-resistant TB (XDR-TB), may be as long as twelve months to two years 
respectively  [21][23] 
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Figure 8: Site of action for TB drugs [24] 
2.10.1.  First line treatment 
The first line TB treatment [Figure 9] comprise of isoniazid (11) (bactericidal, myolic acid 
synthesis inhibitor), rifampicin (12) (bactericidal, DNA dependent RNA polymerase), 
pyrazinamide (13) (bactericidal, fatty acid synthesis inhibitor), ethambutol (14) (bacteriostatic, 
arabinosyl transferase inhibitor). These are taken with pyridoxine to obviate peripheral neuropathy 
that may occur as a result of treatment. [21][23][25][26] 
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   Figure 9: Anti-TB Drugs 
2.10.2.  Second line treatment   
Resistance to either isoniazid or rifampicin may be managed with other first-line drugs, however, 
resistance to both isoniazid and rifampicin (MDR-TB) demands treatment with second-line drugs. 
Second line treatment [Figure 10] include fluoroquinolones (ciprofloxacin (15) and ofloxacin), 
aminoglycosides (kanamycin (16) and amikacin), cyclic peptide antibiotics (capreomycin and 
viomycin); as well as ethionamide (17) and terizidone (18). [21][27][28] 
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Figure 10: Anti-TB Second line treatment Drugs 
2.10.3.  Third line treatment   
Good management of MDR-TB will prevent extensively drug-resistant TB (XDR-TB), an 
extremely challenging and require more finance to treat. Based on the previous treatment history 
and the results of drug susceptibility testing patients with XDR-TB will require an individualized 
approach to treatment regimes. Treatment [Figure 11] amongst others include: linezolid (19), 
imipenem and cilastatin (20) [21][29][30] 
 
Figure 11: Anti-TB Third line treatment Drugs 
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2.11. Anti-Tuberculosis Drug: Mechanism of Resistance  
The spontaneous mutation in genes that encrypt the enzymes or the drug targets that are involved 
in drug activation may result in mycobacterium tuberculosis manifesting resistance to anti-
tubercular drugs. 
Most drug-resistant Mycobacterium tuberculosis are resistant to isoniazid (INH), which is a first-
line drug used to treat tuberculosis. [31] The M. tuberculosis catalase-peroxidase enzyme KatG 
activates Isoniazid (a pro-drug), this activation of INH yields oxygen-derived free radicals (i.e. 
superoxide, hydrogen peroxide, and peroxynitrite) and organic free radicals that hinder the 
development of mycolic acids of the bacterial cell wall, causing DNA destruction and death of the 
bacillus. The mutation of KatG is linked to the decreased drug activity thus prevents the pro-drug 
to convert to it active metabolite leading to INH resistance. The mutation of inhA gene may also 
lead to INH resistance the, resulting in reduced affinity of the enzyme for NADH without affecting 
its enoyl reductase activity [32][33] 
The mutation in the preserved quinolone determining region of gyrA and gryB , involved in the 
drug-DNA gyrase interaction are usually associated with M.tuberculosis resistant to 
fluroquinolones. [34] 
 
Figure 12: Anti-Tuberculosis Drug: Mechanism of Resistance[35]  
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2.12. Antimicrobial activity of Bromo-pyrroles and Cinnamaldehyde derivatives 
1.12.1. Bromo- Pyrroles 
In simple description, a pyrrole is a heterocyclic aromatic five membered compound ring with the 
chemical formula C4H5N. The structure of pyrrole and its substituent positions is shown in figure 
12 
  
Figure 13: Structure of pyrrole and its possible substituent positions 
Pyrroles alkaloids have demonstrated vast significant biological actives such as antimicrobial, 
antiviral, anti-convulsant, anticancer and anti-inflammatory as shown in figure 14 [36]. This has 
qualified a pyrroles to be very importance pharmacophore in medicinal chemistry and organic 
synthesis. [37] 
 
Figure 14: potent biological activity of pyrrole alkaloids [37]  
Figure 15 shows commercially available drugs such as Calcimycin, Ageliferin and Atorvastatin 
that have shown pyrrole as one vital moiety.  
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Figure 15: Marketed drugs with pyrrole moiety 
Calcimycin possesses antibiotic properties against Gram positive bacteria and fungi. It inhibits 
mitochondrial ATPase activity and uncouples oxidative phosphorylation. [38] Atorvastatin is used 
for the treatment of dyslipidemia and prevention of cardiovascular diseases. Ageliferin used 
antibacterial treatment and induces apoptosis in some cells and prevents it in others.  
2.12.2.  Bromination of Pyrroles  
Bromopyrrole alkaloids are known to be one of the most common and essential metabolites 
contained in marine sponges. Studies have indicated that, halogenation of pyrrole at position 4 and 
5 has significant imparted the biological activity particularly bromination in the synthesis of 
organic intermediates such as antitumor, antibacterial and antiviral compounds. Bromination has 
since become a fundamental transformation in pyrrole chemistry and brominated compounds 
serves as a building blocks which is paramount in organic synthesis.   
In a study by (Maria Valeria Raimondi et al) the results of the bromination of 2-(20 
hydroxybenzoyl) pyrrole were reported giving a series of derivatives, related to 
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monodeoxypyoluteorin, whose antimicrobial activity against Staphylococcus aureus increased 
with the degree of halogenation.   
Results from the study by (Rajesh A. Rane et al) further confirms the key role bromination has in 
antibacterial compounds activity as four of the twenty Hybrids reported in the twenty-hybrid 
reported in the study exhibited equivalent antibacterial activity (MIC of 1.56g/mL) compared with 
the standard drug ciprofloxacin against Staphylococcus aureus and Escherichia coli. 
The pyrrole moiety containing carboxamide is found to be essential in most cases for antimicrobial 
activity, recently dihalo-pyrrole carboxamide (Rene A and Telvekar A, 2010) were reported to 
possess good antibacterial activity and also found to important for the antimicrobial activity on the 
biofilm, Figure 15 show other derivative isolated from natural product with their related bio 
activity where Bromopyrrole was a significant scaffold[39][40][41] 
 
Figure 16: Biologically active Bromo pyrrole natural compounds[42] 
Marine sponges are rich sources of natural products and have provided a seemingly infinite supply 
of bioactive metabolites. Bromo pyrrole alkaloids are a well-known class of sponge metabolites 
possessing antibacterial, anti-inflammatory, antifungal effect amongst others, with oroidin as their 
structural prototype. Oroidin analogs emerged as a potent and selective inhibitor of PfFabI with 
IC50 values 0.3 g/mL and anti-plasmodial activity, also showed marginal activity of oroidin  
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towards M.tuberculosis. [39][42] Further Balaram S. Takale et al. evaluated Bromo pyrroles 
molecules for their in vitro antibacterial activities. The compounds exhibited potent activity against 
both Gram positive and negative pathogens, however the two compounds showed promising 
activity against both Gram positive Gram negative bacteria with IC50 value of 1.56 µM. and 3.12 
µM. respectively on comparison with a well know antibiotic Ciprofloxacin with IC50 values of 
0.05µg/ml to 1.6 µg/ml. [40][43] Subsequently, studies by (Deni- SI Haile and Robert E Johnson 
4 1973) pyrroles were sequentially dichloroacetylated or trifluoroacetylated and halogenated.  The 
compounds prepared were assayed for antimicrobial activity and all compounds had in MIC of 
15.6 µg/ml or less against Staphylococcus aureus. 
2.12.3. Synthesis of Bromo pyrroles 
Bromo pyrrole can easily be synthesized from an electrophilic aromatic substitution EAS reaction. 
The general reaction [44][45] 
 
Scheme 1: EAS for pyrrole 
The proposed general reaction mechanism EAS of pyrrole is shown scheme [44][45] 
 
Scheme 2: proposed reaction mechanism of EAS of pyrrole[44]  
The substituent on the pyrrole turns to significantly influence the substitution. An electron 
withdrawing group as such 1,1,1-trichloroethanone (COCCl3) at position 2 turns to influence 
electrophilic substitution at position number 4 and 5. For example bromination of 2,2,2-trichloro-
1-(1H-pyrrol-2-yl)ethan-1-one by bromine in Dichloromethane [43][46][47] 
 
Scheme 3: Bromination of trichloroacetyl pyrroles[43][46][47] 
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2.13. Cinnamaldehyde 
Natural products still serve as a vital source of therapeutic molecules and one such product is 
cinnamon.  For decades, cinnamon has widely been as spices and treatment of certain infections. 
It exhibits no side effects at all. The reported medicinal applications for cinnamon include 
antifungal[48], antibacterial[49], antiviral [50], anti-ulcer [51], anti-oxidant [52] , 
antidiabetic[53], anti-inflammatory[54] and anticancer properties[55]. Furthermore, it has been 
used to treat certain cardiovascular [56] and dental infections [57]  
Cinnamon is made up 4% essential oils of which 60-75% is cinnamaldehyde.[58] Other vital 
constituents of cinnamon include trans-cinnamic acid and eugenol.[59][60] 
   
Figure 17: Potent microbial Cinnamaldehyde derivative  
Cinnamaldehyde is a principal ingredient which its own has equally demonstrated enormous 
biological activity such as anti-insecticidal[61] antimicrobial [62][63], antifungal [64], anti-
inflammatory [65], anticancer[66], and inhibits tumor growth [67] Other Cinnamaldehyde 
derivatives that have demonstrated to very important for treating infections include Palpatine, 
cinromide and Ozagrel.[68]  
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Figure 18: Examples of medically important cinnamaldehyde derivatives [68]  
Palpatine an amide alkaloid isolated from seeds of Piper tuberculatum [69] demonstrated 
antibacterial activity against K. pneumoniae, P. aeruginosa and S. aureus, and antifungal activity 
against Cladosporium sphaerospermun.  However, for both cases no MIC values were reported. 
The toussaintines, a cinnamaldehyde derivatives isolated from Toussaintia orientalis displayed 
promising biological activity. Toussaintine A, B and D all with a cinnamaldehyde moiety 
exhibited (129) anti E. coli at 34 µM, S. aureus and E. coli at 67 µM, and aureus at 17 µM 
respectively.  In literature there are very few reports pertaining to the antimicrobial activity of 
natural cinnamic amides.  
A new series of pyrrole derivatives with potent antibacterial and antifungal activity were 
synthesized using standard amination reaction [41]  
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Scheme 4: Synthetic route of compounds 3a-e 
Synthesized compounds were screened against E.coli and S.aureus for antibacterial activity, 
as well as against A.niger and C.albicans for antifungal activity. Data from the study shows 
that a 4-hydroxyphenyl ring in this studies most potent compound seems to be responsible 
for antifungal activity against C.albicans thus the writers concludes that incorporation of a 4-
hydroxyphenyl ring as a pharmacophoric feature against C.albicans is a promising 
prospect.[70] 
2.14. Scope of research 
In this research work two vital biologically active pharmacophore i.e. bromopyrrole and 
cinnamaldehyde were coupled to develop a hybrid molecule to improve antimicrobial activity. The 
two moieties were coupled by a hydrazone linker which its derivatives have equally displayed 
antibacterial[71], anti-inflammatory, anticancer [72] and antimalaria [73]. For decades, the realms 
of natural products have served significantly in diverse therapeutic treatments and epic of drug 
discovery. Our research work centered on this phenomenon not only for their vast bioactive, but 
for their minimal to non-side effects as well. [43][74] 
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Figure 19 Designing of Bromo pyrrole-cinnamaldehyde hybrid molecule. [75] 
Bromopyrroles and Cinnamaldehyde are two naturally occurring product that have displayed 
profound antimicrobial activity among others that are known for [39][76] Bromopyrroles are 
secondary metabolites from marine sponges (genus Angelas sponges), they are known to have 
diverse pharmacological activity including antimicrobial. Combining them with cinnamaldehyde, 
a well-established naturally occurring antimicrobial agent which shows activity against gram 
positive and gram negative bacteria, Escherichia coli being one of the example amongst 
many.[40][74][7] 
 The antimicrobial activity displayed by both Bromopyrrole and cinnamaldehyde increased the 
interest and a need to do molecular hybridization with an intent to produce novel compounds that 
are potent against microbes. [34][69][77]. In the previous studies the positive mesomeric effect of 
o-methoxy cinnamaldehyde derivative against antifungal activities increased the activity. In this 
study a variety of different groups were screened in an effort to increase the hybrid activity [79].  
These pyrrole hybrids were synthesized from the condensation reaction of Bromopyrroles and 
cinnamaldehyde, forming water as the by-product. 
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3.1.  General Methods 
The synthesized compounds were all characterized using the FT-IR, 1H NMR, 13C NMR spectroscopic 
technique. Analytical grade (AR) chemicals and reagents were obtained from Merck and Sigma-Aldrich. 
The progress of the reactions and the purity of the synthesized compounds were monitored by Thin Layer 
Chromatography on pre-coated silica gel 60 F254 (mesh) (E. Merck) and spots were visualized under UV 
light (long and short wavelength). Compounds were purified by recrystallization technique using ethanol. 
Melting points were determined in open capillaries using (Electro-thermal 9300) digital melting point 
apparatus. 1H and 13C NMR spectra were recorded on the (Bruker Advance IV) NMR spectrometer at 400 
MHz, using DMSO-d6 as a solvent. Perkin Elmer 100 FT-IR spectrophotometer with universal ATR 
sampling accessory was used to record all IR spectra1. 
 
Scheme 5: Synthetic route for the novel series of di-bromopyrrole hybrids 
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3.1.1. Typical general procedure for the synthesis of 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethan-
1-one (2a). 
 
 
 
Trichloroacetyl chloride (13.55g, 74.53 mmol) was dissolving in 50 ml anhydrous diethyl ether. The 
solution was stirred for 30 minutes at room temperature before dropwise addition of freshly distilled pyrrole 
(5g, 74.53 mmol). The reaction mixture was further stirred at room temperature for 2 hours. After reaction 
completion (monitored by the TLC). The reaction was quenched by slowly adding potassium carbonate 
(5g, 36.18 mmol) in 25 ml water. The compound was collected in an organic layer and dried using 
magnesium sulfate. The crude compound was dried under rotavap. The crude was purified by washing in 
Diethyl ether/ Hexane (1:9), filtrating and dried to obtain a pure 2,2,2-trichloro-1-(1H-pyrrol-2-yl) ethan-
1-one 2a. The same procedure was used for methyl pyrrole2(2b).  
3.1.2. Typical General procedure for synthesis of 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-
yl)ethan-1-one- Chloroform(3a): 
 
 
                       
 
0.9 ml of Bromine was added dropwise over period of 1 hour to a solution of 2,2,2-trichloro-1-(1H-pyrrol-
2-yl)ethan-1-one (2a) (5.5 g, 25.88 mmol)  in Chloroform (35ml) at room temperature. The reaction mixture 
was further stirred at room temperature for 1 hour.  A brown effervescence observed.  Sodium carbonate 
was added to the mixture until the efflorescence stopped to release bromine. The reaction completion was 
monitored by TLC. In a Separating funnel the reaction was partition using 50ml of water, the organic phase 
was dried over sodium sulfate and the excess solvent was removed using a rotavap. The crude was purified 
by washing in n-hexane, filtered under vacuum  and dried to obtain a pure compound of  2,2,2-trichloro-1-
(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one Chloroform 3a3.  The same procedure was used for synthesis of 
2(3b). 
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3.1.3. Typical general procedure for synthesis of 4, 5-dibromo-1H-pyrrole-2-carbohydrazide 
(4a)  
                                             
2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one- Chloroform 3 (6 g, 16.21 mmol) was dissolved 
in of ethanol (30 ml). The solution was stirred at room temperature until homogeneous. 3-4 ml of hydrazide 
hydrate was then added to the mixture and the reaction mixture was further stirred at room temperature 
until the precipitate started to appear. The reaction completion was monitored by TLC. The reaction mixture 
was then poured into ice water, precipitate filtered by vacuum, washed with excess n-hexane and dried to 
obtain a pure compound of 4,5-dibromo-1H-pyrrole-2-carbohydrazide 4a. The same procedure was used 
for synthesis of (4b). 
3.1.4. Typical procedure for synthesis of 4, 5-dibromo-N'-((1E, 2E)-3-phenylallylidene)-1H-
pyrrole-2-carbohydrazide (6a-o) 
 
4,5-dibromo-1H-pyrrole-2-carbohydrazide 4 (0.20 g, 7.07 mmol), cinnamaldehyde 5 (0.93g, 7.07 mmol), 
and 3-4 drops of acetic acid in Methanol (4 mL) were charged to microwave for 20 mins at pressure; 150 
PSI and power; 100 Watts4.  The reaction completion was monitored by TLC. The precipitate formed was 
filtered under vacuum, wash with Diethyl ether/n-hexane (1:9). and dried.  Some of the crude compounds 
were further purified by recrystallization in ethanol. The procedure was used for synthesis of 6(a-o) 
3.2. The Anti-TB activity  
 The Anti-TB activity of the synthesized final compounds was carried out on H37Rv 
strain. This was determined by measuring bacterial growth after 5 days in the presence of test compounds. 
Compounds were prepared as 10-point two-fold serial dilutions in DMSO and 
diluted into 7H9-Tw-OADC medium in 96-well plates with a final DMSO concentration of 
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2%. The highest concentration of compound was 200 µM where compounds were soluble in 
DMSO at 10 mM. For compounds with limited solubility, the highest concentration was 50X 
less than the stock concentration e.g. 100 µM for 5 mM DMSO stock, 20 µM for 1 mM 
DMSO stock. For potent compounds, assays were repeated at lower starting concentrations. 
Each plate included assay controls for background (medium/DMSO only, no bacterial cells), 
zero growth (100 µM rifampicin) and maximum growth (DMSO only), as well as a 
rifampicin dose response curve. Plates were inoculated with M. tuberculosis and incubated 
for 5 days: growth was measured by OD590 and fluorescence (Ex 560/Em 590) using a 
BioTek™ Synergy 4 plate reader. Growth was calculated separately for OD590 and RFU5. 
The antitubercular assay was carried out in a collaborative effort at NIH, USA. 
3.3.  Antimicrobial activity 
Results obtained from Anti- TB prompted the research to further evaluate the 4, 5-dibromo-N'-((1E, 2E)-
3-phenylallylidene)-1H-pyrrole-2-carbohydrazide derivatives for their antimicrobial potential against 
several other bacterial strains (gram negative, gram positive and fungal strains) by known MIC assay 
determination method using resazurin dye6. All In vitro antimicrobial activity was conducted in 
collaboration with the Department of Microbiology at Inkosi Albert Luthuli Hospital in Durban (RSA). 
3.3.1. Microorganisms used 
Gram positive microorganism cultures used: Staphylococcus aureus (ATCC 25923), Bacillus 
Subtilis (ATCC 6051). Gram negative microorganism cultures used: Escherichia coli (ATCC 35218), 
Pseudomonas aeruginosa (ATCC 27853). Fungal strains used: Candida albicans (ATCC 90028), 
Cryptococcus neoformans (ATCC 66031), Aspergillus Niger (ATCC 16404). The microorganism culturing 
and sub culturing was performed a day before the commencement of actual testing. 
3.3.2. Preparation of medium 
22g of Muller-Hinton Broth containing (Acid Hydrolysate of Casein, Beef Extract and Starch) was 
dissolved in 1 L of double distilled water (ddH2O). The pH of this medium was adjusted to 7.4 ± 0.1 and 
sterilized by autoclave for 15 min at 121°C. The solution was allowed to cool and stored at a temp of 4°C. 
Sterility check was performed by incubating uninoculated media in an aerobic incubator at 37 °C for 18-24 
h. For antifungal activity, RPMI 1640 medium with L-glutamine and 0.165 M MOPS and without sodium 
bicarbonate (Lonza) was used. 
 
 
CHAPTER 3 
 
 
Andile P Dlungele                                                             42                                                                UKZN-2018 
 
 
3.3.3.  Preparation of test compounds (stock solution and working standard) 
A quantity of 4.000 mg of the synthesized final compounds and standard drug (Amoxicillin and 
/Amphotericin B) were dissolved in 1 ml of DMSO to give stock solution (4000 µg/ml). Further, 100 µl of 
stock solution was diluted with 900 µl of ddH2O to afford working standard solution at a concentration of 
400 µg/ml. 
References:  
 
1.  Joshi SD, Kumar D, Dixit SR, et al. European Journal of Medicinal Chemistry Synthesis , 
characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes. 
Eur J Med Chem. 2016;121:21-39. doi:10.1016/j.ejmech.2016.05.025. 
2.  Bairwa R, Kakwani M, Tawari NR, et al. Bioorganic & Medicinal Chemistry Letters Novel 
molecular hybrids of cinnamic acids and guanylhydrazones as potential antitubercular agents. 
Bioorg Med Chem Lett. 2010;20(5):1623-1625. doi:10.1016/j.bmcl.2010.01.031. 
3.  Zeng Y, Cao R, Yang J, Li X, Li S. European Journal of Medicinal Chemistry Design , synthesis 
and biological evaluation of novel HSP70 inhibitors : N , N 0 -disubstituted thiourea derivatives. 
Eur J Med Chem. 2016;119:83-95. doi:10.1016/j.ejmech.2016.04.042. 
4.  Kalemba D, Kunicka A. Antibacterial and Antifungal Properties of Essential Oils. 2003:813-829. 
5.  Ollinger J, Bailey MA, Moraski GC, et al. A Dual Read-Out Assay to Evaluate the Potency of 
Compounds Active against Mycobacterium tuberculosis. 2013;8(4):1-9. 
doi:10.1371/journal.pone.0060531. 
6.  Palomino J, Martin A, Camacho M, Guerra H, Swings J. Resazurin Microtiter Assay Plate : Simple 
and Inexpensive Method for Detection of Drug Resistance in Mycobacterium tuberculosis. 
2002;46(8):2720-2722. doi:10.1128/AAC.46.8.2720.
CHAPTER 4 
Andile P Dlungele                                                             43                                                                UKZN-2018 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Results & Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
Andile P Dlungele                                                             44                                                                UKZN-2018 
 
 
4.1. Chemistry 
The research project comprised of 15 novel compounds (6a-6o) of di-bromopyrrole hybrids 
substituted with cinnamaldehyde derivatives (Scheme 4). These were synthesized by means of 
trichloroacetylation of 1H-pyrrole and N-Methyl substituted Pyrrole using equimolar quantity of 
trichloroacetyl chloride, yielding 2-trichloroacetylpyrrole 2a & 2b in excellent yield (89%). 
Compound 2a and 2b was then brominated using 2 equivalent of bromine in chloroform for two 
hours, giving 4, 5-dibromo-2-trichloroacetyl-1H-pyrrole 3a and 3b in excellent yield (87%).  
Bromopyrrole 3a & 3b was then reacted with excess amount of hydrazine hydrate at room 
temperature to give its acid hydrazide derivative 4a & 4b in good yield (80%). The Microwave 
assisted Schiff base reaction between acid hydrazide 4a & 4b with cinnamaldehyde derivatives 
(5) proceeds without the requirement of a catalyst, yielding the desired di-bromopyrrole 
cinnamaldehyde hybrids 6a-o. All the synthesized compounds were confirmed by the spectral data 
(IR, 1H NMR, 13C NMR and MS) which was in complete agreement with the proposed structures. 
[M]+ Molecular ion peak confirmed the molecular weight of the parent ions while [M+2]+ and 
[M+4]+ peaks confirmed the presence of two bromine atoms in the pyrrole ring with a ratio of 1:1, 
indicating two bromine isotopes 79Br and 81Br . The 1H NMR spectra of compounds 2-4 showed 
singlet peak resonating between 12.8–13.0 which corresponds to the N–H of the pyrrole core.  
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Scheme 5: Synthetic route for the novel series of di-bromopyrrole hybrids substituted with 
cinnamaldehyde derivatives 
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4.1.1. Physicochemical properties  
The synthesized compounds appeared as yellowish and brown, colored solids. The percentage (%) 
yield of the synthesized compounds (6a-o) ranged from 23% - 91 %. The melting points for the 
synthesized compounds from were found to be between 199 and 228°C (Table 1).  
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Table 1: Physicochemical properties of di-bromopyrrole hybrids substituted with cinnamaldehyde derivatives  
Comp.No R1(H/Me) R2 R3 R4 %Yield M.P.
a(°C) Appearance MF MW 
6a 4-N(CH3)2 R2=4-N(CH3)2 R3=H R4=H 90 204-206 Yellow 
Powder 
C16H16Br2N4O 440.14 
6b -H- R2=H                   R3=H R4=H 23 217-219 Yellow 
Powder 
C14H11Br2N3O 397.07 
6c CH3 R2=H                   R3= CH3 R4=H 55 202-204 Yellow 
Powder 
C15H13Br2N3O 411.1 
6d 2-MOe R2=2-OMe R3=H R4=H 63 203-205 Brown 
Powder 
C15H13Br2N3O2 427.1 
6e 4- Cl R2=4-Cl R3=H R4=H 33 223-225 Yellow 
Powder 
C14H10Br2ClN3O 431.51 
6f 2-NO2 R2=2-NO2 R3=H R4=H 64 206-208 Yellow 
Powder 
C15H12Br2N4O3 442.07 
6g 4-N(CH3)2 R2=4-N(CH3)2 R3=H R4=H 33 212-214 Yellow 
Powder 
C17H18Br2N4O 454.17 
6h -H- R2=H                  R3=H R4=H 46 204-206 Yellow 
Powder 
C15H13Br2N3O 411.1 
6i CH3 R2=H                 R3= CH3 R4=H 91 117-199 Yellow 
Powder 
C16H15Br2N3O 
 
425.12 
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6j 2-MOe R2=2-OMe         R3=H R4=H 66 203-205 Yellow 
Powder 
C16H15Br2N3O2 441.12 
6k 4-MOe R2=4-OMe         R3=H R4=H 80 207-209 Yellow 
Powder 
C16H15Br2N3O2 441.12 
6l Ph R2=H                 R3=H R4=H 70 200-202 Yellow 
Powder 
C21H17Br2N3O 487.2 
6m 4- Cl R2=4-Cl             R3=H R4=Ph 70 221-223 Yellow 
Powder 
C15H12Br2ClN3O 445.54 
6n 2-NO2 R2=2-NO2          R3=H R4=H 81 218-221 Yellow 
Powder 
C15H12Br2N4O3 456.09 
6o -H-  R2=H                R3=CH3 R4=H 35 119-201 Yellow 
Powder 
C15H15Br2N3O 413.11 
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4.1.2. Spectroscopic Data 
Structural interpretation was carried out by means of the following spectroscopic techniques, viz. 
FT-IR, 1H NMR, 13CNMR and EI-MS) which are depicted in the Table 2 and the respective spectra 
for all the compounds were incorporated as appendix. 
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Table 2 Spectroscopic data of di-bromopyrrole hybrids substituted with cinnamaldehyde derivatives (4a-o) 
Compound IR [ATR, νmax, cm-1] 1H NMR [400 MHz, DMSO-d6, δ, 
ppm] 
13C NMR [101 MHz, 
DMSOd6, δ, ppm] 
EIMS 
(m/z) 
6a IR γmax (neat):  3227.93, 
3160.67, 1603.21, 
1559.84, 1359.11, 
1315.34, 1226.91, 
1055.01, 971.72, 867.44, 
803.15, 755.61, 661.55, 
596.91, 522.82 
1H-NMR (400 MHz, DMSO):  δ 12.90 
(s, 1H, -NH), 11.28 (s, 1H, -CO-NH-), 
8.05 (d, J= 8Hz, 1H, -N=CH-C-), 7.43 
(m, 2H, Ar-H), 7.07 (m, 1H, Pyrrole 
3H ), 6.87 (m, 2H, -C=CH-Ar,  -C-
CH=C-), 6.70 (m, 2H, 2×Ar-H), 2.94 
(s, 6H, 2×N-CH3) 
13C NMR (100 MHz 
DMSO,): δ 150.76, 149.91, 
139.75, 139.51, 130.43, 
128.46, 128.42, 123.75, 
123.70, 122.37, 120.43, 
113.32, 112.06, 111.97 
437.13 (M+) 
6b IR γmax (neat): 3127.40, 
3026.20, 1623.06, 
1539.89, 1477.98, 
1347.99, 1246.79, 972.91, 
847.47, 800.97, 743.09, 
716.39, 677.63, 597.76, 
548.32 
1H-NMR (400 MHz, DMSO)  δ 12.97 
(s, 1H, -NH), 11.45 (s, 1H, -CO-NH-), 
8.11 (s, 1H, -N=CH-C-), 7.62 (m, 2H, 
2×Ar-H), 7.32 (m, 3H, 3×Ar-H), 7.04 
(m, 3H, Pyrrole 3H, -C=CH-Ar,  -C-
CH=C-) 
13C NMR (100 MHz, 
DMSO: δ 155.28, 148.89, 
138.84, 135.98, 128.87, 
127.12, 125.61, 113.60 
394.93 (M+) 
6c IR γmax (neat): 3143.65, 
3027.6, 2952.12, 1625.47, 
1541.56, 1479.52, 
1414.12, 139.03, 1249.88, 
1024.49, 970.35, 847.28, 
1H-NMR (400 MHz, DMSO)  δ 13.31 
(s, 1H, -NH), 11.77 (s, 1H, -CO-NH-), 
8.49 (s, 1H, -N=CH-C-), 7.75 (m, 5H, 
5×Ar-H), 7.46 (s, 1H, -C-CH=C-)), 
13C NMR (100 MHz, 
DMSO): δ 152.18, 136.74, 
136.33, 129.38, 129.29, 
128.50, 127.77, 106.86, 
98.19 
407.93 (M+) 
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747.13, 719.19, 684.98, 
603.04 
7.21 (s, 1H, Pyrrole 3H), 2.86 (s, 3H, 
CH3-C-) 
6d IR γmax (neat): 3136.16, 
3042.82, 2963.80, 
2836.50, 1614.36, 
1564.57, 1483.17, 
1390.37, 1241.96, 
1025.43, 977.10, 833.52, 
740.39, 600.23 
1H-NMR (400 MHz, DMSO)  δ 12.95 
(s, 1H, -NH), 11.37 (s, 1H, -CO-NH-), 
8.07 (d, J= 7.6Hz, 1H, -N=CH-C-), 
7.56 (m, 2H, 2×Ar-H), 6.99 (m, 5H, 
2×Ar-H, pyrrole 3H, -C=CH-Ar,  -C-
CH=C-) 
13C NMR (100 MHz 
DMSO,): δ 159.92, 149.32, 
138.72, 128.71, 128.67, 
123.28, 114.35, 113.48, 
106.08, 98.18, 55.28 
424.93 (M+) 
6e IR γmax (neat): 3325.09, 
3149.36, 2949.08, 
1629.82, 1539.90, 
1479.61, 1349.11, 
1246.46, 1084.15, 973.11, 
852.28, 805.17, 749.70, 
699.42 
1H-NMR (400 MHz, DMSO):  δ 12.98 
(s, 1H, -NH), 11.47 (s, 1H, -CO-NH-), 
8.10 (s, 1H, -N=CH-C-), 7.65 (m, 2H, 
2×Ar-H), 7.43 (m, 2H, 2×Ar-H), 7.06 
(m, 3H, Pyrrole 3H,  -C=CH-Ar,  -C-
CH=C-) 
13C NMR (100 MHz, 
DMSO): δ 148.58, 137.30, 
134.97, 133.13, 128.83, 
128.77, 126.45, 113.61, 
106.29, 98.21 
427.87 (M+) 
6f IR γmax (neat): 3639.65, 
3440.79, 3296.32, 
3150.21, 2956.4, 1642.98, 
1572.62, 1544.28, 
1515.11, 1347,16, 
1255.30, 1081.95, 965.75, 
1H-NMR (400 MHz, DMSO):  δ 13.00 
(s, 1H, -NH), 11.55 (s, 1H, -CO-NH-), 
8.14 (s, 1H, -N=CH-C-), 8.05-7.99 
(m, 2H, 2×Ar-H), 7.62-7.72 (m, 1H, 
Ar-H), 7.59-7.55 (m, 1H, Ar-H), 7.14-
13C NMR (100 MHz, 
DMSO): δ 147.83, 133.86, 
133.54, 132.43, 130.46, 
130.20, 129.53, 128.30, 
128.14, 124.84, 124.58 
439.91 (M+) 
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834.01, 737.10, 694.17, 
651.97 
7.10 (m, 3H, Pyrolle 3H, -C=CH-Ar,  
-C-CH=C-) 
6g IR γmax (neat): 3155.57, 
2890.00, 2283.50, 
1635.88, 1589.80, 
1519.11, 1283.03, 
1155.46, 1063.00, 942.66, 
827.12, 797.21, 707.91, 
646.91 
1H-NMR (400 MHz, DMSO):  δ 11.32 
(s, 1H, -CO-NH-), 8.05 (d, J = 8Hz, 
1H, -N=CH-C-), 7.43 (m, 2H, 2×Ar-
H),  7.09 (s, 1H, Pyrrole 3H), 6.86 (d, 
J =16Hz, 1H, -C=CH-Ar), 6.78-6.69 
(m, 3H, -C=CH=C-2×Ar-H), 3.88 (s, 
3H, -N-CH3), 2.94 (s, 6H, -N(CH3)2) 
13C NMR (100 MHz, 
DMSO): δ 155.75, 150.09, 
150.15, 139.77, 130.39, 
128.41, 126.72, 123.64, 
120.39, 144.07, 111.95, 
111.5, 97.09, 38.89, 35.49 
451.99 (M+) 
6h IR γmax (neat): 3190.48, 
3150.65, 3021.13, 
1631.28, 1535.43, 
1446.81, 1404.35, 
1243.01, 1050.98, 979.94, 
885.21, 749.26, 714.63, 
685.93 
1H-NMR (400 MHz, DMSO):  δ 11.44 
(s, 1H, -CO-NH-), 8.07 (s, 1H, -
N=CH-C-), 7.59-7.57 (m, 2H, 2×Ar-
H), 7.36-7.28 (m, 3H, Ar-H), 7.09 (s 
1H, Pyrrole 3H), 7.0 (m, 2H, -C=CH-
Ar,  -C-CH=C-), 3.84 (s, 3H, -N-CH3) 
 
13C NMR (100 MHz, 
DMSO): δ 138.88, 135.92, 
128.82, 127.09, 126.48, 
125.57, 111.90, 97.15, 35.54 
407.93 (M+) 
6i IR γmax (neat): 3382.15, 
320.43, 3114.30, 3020.21, 
2232.78, 1619.72, 
1547.44, 1390.44, 
1337.34, 1250.67, 
1162.57, 1081.01, 953.44, 
1H-NMR (400 MHz, DMSO):  δ 11.47 
(s, 1H, -CO-NH-), 8.11 (s, 1H, -
N=CH-C-), 7.44-7.40 (m, 4H, 4×Ar-
H), 7.31 (m, 1H, Ar-H), 7.12 (s, 1H, 
Pyrrole 3H), 6.83 (s, 1H, -C=CH-Ar), 
13C NMR (100 MHz, 
DMSO): δ 152.52, 136.89, 
136.50, 134.58, 129.55, 
128.65, 127.92, 115.03, 
112.01, 97.34, 35.70, 13.05 
422.95 (M+) 
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911.76, 824.09, 778.46, 
723.11, 692.93, 616.91 
3.89 (s, 3H, -N-CH3), 2.11 (s, 3H, 
=CH-CH3) 
6j IR γmax (neat): 3206.46, 
3034.84, 2955.23, 
2830.13, 1621.31, 
1540.56, 1483.94, 
1451.42, 1411.82, 
1243.60, 1036.79, 953.14, 
886.40, 860.12, 781.96, 
746.96, 653.73 
1H-NMR (400 MHz, DMSO):  δ 11.44 
(s, 1H, -CO-NH-), 8.09 (s, 1H, -
N=CH-C-), 7.65-7.63 (m, 1H, Ar-H), 
7.34-7.30 (m, 1H, Ar-H), 7.18-7.03 
(m, 4H, =CH-Ar , Pyrrole 3H, 2×Ar-
H), 6.98 (m, 1H, --C-CH=C-), 3.88-
3.86 (s, 6H, -N-CH3, -OCH3) 
 
 
 
13C NMR (100 MHz, 
DMSO): δ 156.86, 149.82, 
124.20, 120.72, 11.55, 
97.16, 55.56, 35.52 
438.95 (M+) 
6k IR γmax (neat): 3748.42, 
3207.82, 3032.32, 
2967.50, 2835.09, 
2337.54, 1696.25, 
1649.15, 1572.38, 
1534.96, 1504.42, 
1452.47, 1354.7, 1248.62, 
1168.33, 1110.80, 
1019.21, 967.51, 806.08, 
717.55, 675.44, 642.13 
1H-NMR (400 MHz, DMSO):  δ 11.40 
(s, 1H, -CO-NH-), 8.08 (s, 1H, -
N=CH-C-), 7.57-7.55 (m, 2H, 2×Ar-
H), 7.11 (s, 1H, Pyrrole 3H), 6.96-6.85 
(m, 4H, 2×Ar-H Pyrrole 3H, -C=CH-
Ar,  -C-CH=C-),  3.88 (s, 3H,-OCH3), 
3.78 (s, 3H, -N-CH3) 
13C NMR (100 MHz 
DMSO,): δ 159.88,138.78, 
128.64, 123.23, 114.82, 
114.30, 111.75, 97.12, 
55.23, 35.49  
438.95 (M+) 
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6l IR γmax (neat): 3262.96, 
3186.64, 3025.37, 
1643.24, 1602.75, 
1546.45, 1443.67, 
1334.48, 1245.26, 
1120.15, 1001.90, 958.24, 
912.46, 822.98, 771.39, 
697.73, 634.80, 566.58 
1H-NMR (400 MHz, DMSO):  δ 11.40 
(s, 1H, -CO-NH-), 7.92 (d, J = 8Hz, 
1H, -N=CH-C-), 7.52-7.46 (m, 3H, 
3×Ar-H), 7.39-7.34 (m, 5H, 5×Ar-H), 
7.32-7.30 (m, 2H, 2×Ar-H), 7.04  (s, 
1H, Pyrrole 3H), 6.9 (d, J = 8Hz, 1H, 
-HC=C-Ar), 3.87 (s, 3H, -N-CH3) 
13C NMR (100 MHz, 
DMSO): δ 155.86, 148.0, 
147.03, 140.43, 138.09, 
129.99, 128.63, 128.59, 
128.19, 127.34, 126.3, 
124.18, 114.98, 111.9, 
97.14, 35.53 
483.96 (M+) 
6m IR γmax (neat): 3149.70, 
2955.80, 1643.89, 
1523.22, 1485.91, 
1422.96, 1295.01, 
1210.92, 1086.90, 962.20, 
850.44, 765.87, 722.81, 
649.03, 604.77 
1H-NMR (400 MHz, DMSO):  δ 
11.50 (s, 1H, -CO-NH-), 8.09 (s, 1H, -
N=CH-C-), 7.65-7.63 (m, 2H, 2×Ar-
H), 7.44-7.42 (m, 2H, 2×Ar-H), 7.13 
(m, 1H, Pyrrole 3H), 7.05-7.03 (m, 
2H, -C=CH-Ar,  -C-CH=C-), 3.88 (s, 
3H, -N-CH3) 
13C NMR (100 MHz, 
DMSO): δ 148.86, 137.41, 
134.92, 133.15, 128.82, 
128.77, 126.42, 115.02, 
112.00, 97.19, 35.50 
441.89 (M+) 
6n IR γmax (neat): 3156.45, 
2956.6, 1645.62, 1615.25, 
1511.57, 1417.50, 
1346.82, 1250.46, 
1147.82, 963.04, 861.07, 
829.45, 739.58, 713.80, 
612.99, 536.10. 
1H-NMR (400 MHz, DMSO):  δ 11.58 
(s, 1H, -CO-NH-), 8.14 (s, 1H, -
N=CH-C-), 8.00-7.98 (m, 2H, 2×Ar-
H), 7.75-7.71 (m, 1H, Ar-H), 7.59-
7.55 (m, 1H, Ar-H), 7.30-7.28 (d, J = 
16Hz, 1H, =CH-Ar-H), 7.15-7.07 (m, 
13C NMR (100 MHz, 
DMSO): δ 147.83, 133.57, 
132.58, 130.44, 130.17, 
129.56, 128.33, 126.30, 
124.59, 112.24, 97.26, 30.69 
453.92(M+) 
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2H, Pyrrole 3H, -C-CH=C-), 3.89 (s, 
3H, -CH3) 
6o IR γmax (neat): 3247.70, 
3120.64, 3023.67, 
2943.86, 1881.45, 
1641.72, 1568.80, 
1541.57, 1449.51, 
1356.89, 1243.74, 155.02, 
1041.60, 953.71, 854.42, 
817.95, 701.56, 636.10, 
608.5, 568.76 
1H-NMR (400 MHz, DMSO):  δ 11.20 
(s, 1H, -CO-NH-), 7.64 (s, 1H, -
N=CH-C-), 7.31-7.24 (m, 4H, 4×Ar-
H), 7.21-7.19 (m, 1H, Ar-H), 7.02 (m, 
1H, Pyrrole 3H), 3.85 (s, 3H, -CH3), 
2.81-2.79 (m, 2H, =CH-CH2-), 2.5 (m, 
2H, -CH2-Ar) 
13C NMR (100 MHz, 
DMSO): δ 155.87, 150.70, 
140.88, 128.35, 128.33, 
126.40, 125.94, 114.54, 
111.43, 96.96, 35.4, 33.64, 
31.93 
419.95M+) 
CHAPTER 4 
Andile P Dlungele                                                             56                                                                UKZN-2018 
 
4.1.3. Spectral analysis and elucidation 
4.1.3.1.Infra-red spectroscopy 
Infra-red spectroscopy served as an analytical tool in the identification of different functional 
groups in all the synthesized novel compounds. The characteristic bands of all compounds were 
identified to be the amine at N-H stretches which ranged from 31606.07– 3227.93 cm-1, the 
compounds also reflected a consistent prominent peak around 1600.00 – 1608.00 cm-1 which 
indicated the presence of a carbonyl group (C=O) in all the synthesized compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: IR spectrum of compound 6a 
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Figure 21: IR spectrum of compound 6b 
 
All synthesized compounds showed resemblance of the characteristic peaks in the IR spectrum 
which further confirms the presence of the expected functional groups in the newly synthesized 
compounds 
 
4.1.3.2. 1H NMR Spectroscopy 
Proton NMR experiment was conducted to confirm the structure of the newly synthesized 
compounds. From the1H NMR spectra of the final compounds (6a-o), the N-Methyl group at 2.95 
ppm integrated to 6 protons. There is an inner proton singlet around d 8.1-8.7 in all compounds. 
The double bond together with the aryl protons from cinnamaldehyde resonate in the range of d 
6.7-7.5 
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Figure 22: 1H NMR spectrum of compound 6a 
 
 
4.1.3.3.  13C NMR spectroscopy 
13C NMR was also used to evaluate and determine the presence of carbon atoms of the synthesized 
compounds. Formation of compounds (6a-o) was confirmed by the appearance of N-Methyl 
groups resonating at 39.8ppm and the amide group at 150.76. The various aromatic carbons 
resonated between δ 111.97 – 139.75 ppm as shown in the figure 14. All of the synthesized 
compounds were found to contain the expected number of carbon atoms. 
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Figure 23: 13C NMR spectrum of compound 6a 
4.2.  In vitro biological assay 
All the synthesized derivatives were evaluated for their antimicrobial potential against several 
bacterial strains (gram negative and gram positive) by known MIC assay determination method 
using resazurin dye1,2 (Table 3). 
4.2.1. Microorganism used 
Gram positive microorganism cultures used: Staphylococcus aureus (ATCC 25923), Bacillus 
Subtilis (ATCC 6051). Gram negative microorganism cultures used: Escherichia coli (ATCC 
35218), Pseudomonas aeruginosa (ATCC 27853), Fungal strains used: Candida albicans 
(ATCC90028), Cryptococcus neoformans (ATCC 66031), Aspergillus Niger (ATCC 16404). The 
culturing and sub culturing of microorganism were performed a day before the actual testing and 
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the antimicrobial assay was carried out in a collaborative effort at the Department of Microbiology, 
Inkosi Albert Luthuli hospital, Durban, South Africa 
4.2.2. Discussion of Pharmacological evolution studies: 
All the synthesized compounds (6a-6o) were screened for their in vitro antibacterial activity 
against a series of microorganisms, which comprised of two Gram +ve [Staphylococcus aureus 
ATCC25923, Bacillus subtilis ATCC6051] and two Gram –ve [Escherichia coli ATCC35218, 
Pseudomonas aeruginosa ATCC27853]. The MIC results were poor as seen from the table 3 
below. Antifungal evaluation was carried out against three fungal strains [Candida albicans 
ATCC90028, Cryptococcus neoformans ATCC66031 and Aspergillus Niger ATCC16404] and 
two well characterized clinical isolates strains of Candida albicans and Cryptococcus neoformans. 
The MIC results of the synthesized compounds exhibited promising antifungal activity (MICs = 
12.56-50 μg/mL), especially against Cryptococcus neoformans as depicted in table 3 below.  The 
MIC values ranged from 12.5 - >200 µg/mL and all compounds exhibited poor to moderate in-
vitro activity against the screened bacterial strains. The reference drug Amoxicillin indicated an 
MIC of 0.39 µg/mL. However, a systematic analysis of the data also revealed that some of the 
synthesized compounds exhibited promising antifungal activity (MICs = 12.5-50 μg/mL), 
especially against Cryptococcus neoformans. The reference drug Amphotericin B an MIC of 0.39-
1.5μg/mL.  
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Table 3: Antimicrobial activity data 
 
ATCC 
25923 
ATCC 
35218 
ATCC 
27853 
ATC
C 
6051 
 ATC
C 
9002
8 
ATCC 
66031 
ATCC 
16404 
 
Staphyloc
occus 
aureus 
Escheri
chia 
coli  
Pseudom
onas 
aerugino
sa  
Bacil
lus 
subtil
is 
 Cand
ida 
albic
ans 
C. 
Neofor
mans 
Aspergi
llus 
Niger 
6a >200 >200 >200 >200  >200 >200 >200 
6b >200 >200 >200 >200  >200 25 >200 
6c >200 >200 >200 >200  >200 >200 >200 
6d >200 >200 >200 >200  >200 >200 >200 
6e >200 >200 >200 >200  >200 12.5 >200 
6f >200 >200 >200 >200  >200 12.5 >200 
6g >200 >200 >200 >200  >200 25 >200 
6h >200 >200 >200 >200  >200 12.5 >200 
6i >200 >200 >200 >200  >200 >200 >200 
6j >200 >200 >200 >200  >200 25 >200 
6k >200 >200 >200 >200  >200 >200 >200 
6l >200 >200 >200 >200  >200 12.5 >200 
6m >200 >200 >200 >200  >200 >200 >200 
6n >200 >200 >200 >200  >200 >200 >200 
6o >200 >200 >200 >200  50 >200 >200 
Amoxic
illin  
<0.39 <0.39 <0.39 <0.39 Amphote
ricin B 
<0.39 1.5 <0.39 
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The synthesized novel compounds were also evaluated against M. tuberculosis H37Rv strain 
(Table 4). The antitubercular activity of these compounds was carried out at National Institute of 
Allergy and Infectious Diseases (NIAID) screening program, Bethesda, MD, USA. Four of the 
synthesized compounds (6b-6e) displayed moderate activity the rest of the synthesized compound 
had poor activity against mycobacterial strain. 
 
Table 4: Antitubercular activity data (MIC in µM) of a series of novel derivatives (6a-o) 
 
Compound Mycobacterium tuberculosis 
(H37Rv) 
6a >200 
6b >20 
6c >20 
6d >20 
6e >20 
6f >200 
6g >200 
6h >200 
6i >200 
6j >200 
6k >200 
6l >200 
6m >200 
6n >200 
6o >200 
Rifampicin 0.0067 
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5.1.  Conclusion  
The aim of this study was to investigate the effectiveness of fifteen newly synthesized derivatives 
of bromopyrroles against antitubercular and antimicrobial potential of these derivatives. To a great 
extent, this work has accomplished the aims of the study. Results from this work confirmed the 
following conclusions: These synthesized hybrids displayed promising activity against tested 
fungal strains, in particular for clinical isolate of C. neoformans with MIC values ranging from 
12.5 – 25 µg/mL. The sythesised compounds also displayed moderate activity (MIC >20 μM) in 
four synthesized compounds (4b-e) against M. tuberculosis H37Rv.  
5.2.  Future Studies 
The antifungal activity displayed by compounds 6e-h and 6l against Cryptococcus neoformans 
indicates that these substituted hybrids can be further exploited to develop potential antifungal 
agents. In addition, these active hybrids 6b-6e also displayed moderate activity (MIC >20 μM) 
against M. tuberculosis H37Rv. The encouraging antifungal and anti-mycobacterial activity of 
synthesized novel bromopyrrole derivatives indicated the potential for further research into the 
development antifungal agents against the resistant clinical isolates.
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Spectrum 1: 1H NMR spectrum of compound 6a 
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Spectrum 2: 13C NMR spectrum of compound 6a 
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Spectrum 3: IR spectrum of compound 6a 
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Spectrum 4: 1H NMR spectrum of compound 6b 
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Spectrum 5: 13C NMR spectrum of compound 6b 
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Spectrum 6: IR spectrum of compound 6b 
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Spectrum 7: 1H NMR spectrum of compound 6c 
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Spectrum 8: 13C NMR spectrum of compound 6c 
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Spectrum 9: IR spectrum of compound 6c 
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Spectrum 10: Mass spectrum of compound 6c 
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Spectrum 11: 1H NMR spectrum of compound 6d 
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Spectrum 12: 13C NMR spectrum of compound 6d 
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Spectrum 13: IR spectrum of compound 6d 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
Andile P Dlungele                                                             79                                                                UKZN-2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spectrum 14: 1H NMR spectrum of compound 6e 
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Spectrum 15: 13C NMR spectrum of compound 6e 
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Spectrum 16: IR spectrum of compound 6e 
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Spectrum 17: Mass spectrum of compound 6e 
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Spectrum 18: 1H NMR spectrum of compound 6f 
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Spectrum 19: 13C NMR spectrum of compound 6f 
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Spectrum 20: IR spectrum of compound 6f 
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Spectrum 21: 1H NMR spectrum of compound 6g 
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Spectrum 22: 13C NMR spectrum of compound 6g 
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Spectrum 23: IR spectrum of compound 6g 
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Spectrum 24: 1H NMR spectrum of compound 6h 
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Spectrum 25: 13C NMR spectrum of compound 6h 
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Spectrum 26: IR spectrum of compound 6h 
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Spectrum 27: Mass spectrum of compound 6h 
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Spectrum 28: 1H NMR spectrum of compound 6i 
 
 
 
 
 
 
 
 
 
 
Appendix 
Andile P Dlungele                                                             94                                                                UKZN-2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spectrum 29: 13C NMR spectrum of compound 6i 
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Spectrum 30: IR spectrum of compound 4i 
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Spectrum 31: 1H NMR spectrum of compound 6j 
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Spectrum 32: 13C NMR spectrum of compound 6j 
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Spectrum 33: IR spectrum of compound 6j 
 
 
 
Appendix 
Andile P Dlungele                                                             99                                                                UKZN-2018 
 
 
 
 
 
Spectrum 34: Mass spectrum of compound 6j 
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Spectrum 35: 1H NMR spectrum of compound 6k 
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Spectrum 36: 13C NMR spectrum of compound 6k 
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Spectrum 37: IR spectrum of compound 6k 
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Spectrum 38: Mass spectrum of compound 6k 
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Spectrum 39: 1H NMR spectrum of compound 6l 
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Spectrum 40: 13C NMR spectrum of compound 6l 
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Spectrum 41: IR spectrum of compound 6l 
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Spectrum 42: Mass spectrum of compound 6l 
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Spectrum 43: 1H NMR spectrum of compound 6m 
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Spectrum 44: 13C NMR spectrum of compound 6m 
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Spectrum 45: IR spectrum of compound 6m 
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Spectrum 46: Mass spectrum of compound 6m 
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Spectrum 47: 1H NMR spectrum of compound 6n 
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Spectrum 48: 13C NMR spectrum of compound 6n 
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Spectrum 49: IR spectrum of compound 6n 
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Spectrum 50: 1H NMR spectrum of compound 6o 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
Andile P Dlungele                                                             116                                                                UKZN-2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spectrum 51: 13C NMR spectrum of compound 6o 
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Spectrum 52: IR spectrum of compound 6o 
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Spectrum 53: IR spectrum of compound 6o 
 
 
 
 
 
